Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
Aardvark Therapeutics Inc. (NASDAQ:AARD) is one of the best young stocks with huge upside potential.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 3,917,299 | $14,768,217 | 2.23% | |
| 2. | Citadel Investment Group Ken Griffin | 1,242,777 | $4,685,269 | -4% | 0% |
| 3. | Laurion Capital Management Benjamin A. Smith | 1,034,459 | $3,899,910 | +2% | 0.17% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 300,000 | $1,131,000 | 0% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 163,355 | $615,848 | +524% | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.40 | 3,000 | $43,200.00 | 108,484 | 2025-12-11 | Filing | |
| $14.49 | 7,000 | $101,395.00 | 1,551,613 | 2025-12-11 | Filing | |
| $9.94 | 3,500 | $34,804.70 | 1,543,384 | 2025-09-15 | Filing | |
| $9.51 | 6,500 | $61,818.90 | 1,539,884 | 2025-09-15 | Filing | |
| $8.50 | 5,000 | $42,515.50 | 1,533,384 | 2025-09-12 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 792,571 | $2,987,992 | 0% | |
| 2. | 554,101 | $2,088,961 | 0% | |
| 3. | 316,621 | $1,193,661 | 0.23% | |
| 4. | 309,449 | $1,166,884 | 0% | |
| 5. | 199,322 | $751,444 | 0% |